A modified Delphi consensus process (June 2025–March 2026) among 51 international experts to establish recommendations for low-dose oral minoxidil (LDOM) use in children aged <12 years with hair disorders, covering patient selection, dosing, safety, and monitoring.
84 of 127 items reached ≥70% consensus: LDOM was supported for hair follicle miniaturization (100%), hair cycle abnormalities (100%), hair shaft disorders (84%), and adjunctive use in select scarring alopecia (98%) in children aged ≥4 to <12 years. Fixed dosing by weight (<20 kg: 0.250–0.625 mg; 20–40 kg: 1.250 mg; >40 kg: 1.875 mg) and weight-based dosing (0.01–0.02 mg/kg/d) both achieved consensus; escalation of 50–100% with reassessment every 3–6 months was endorsed. Routine baseline labs and BP monitoring were not deemed universally necessary in low-risk patients.
Full text was not accessible; findings derive from the abstract only. The process captured only clinicians treating >10 pediatric patients with LDOM, potentially biasing toward experienced adopters. Consensus does not substitute for controlled efficacy or safety trial data.
Clinicians treating children aged ≥4 to <12 years with hair disorders can use LDOM as a structured, off-label option, selecting between fixed weight-based or mg/kg dosing and combining with agents like spironolactone or JAK inhibitors as the alopecia subtype warrants. Absolute contraindications are pericardial effusion/tamponade and pheochromocytoma; routine monitoring can be individualized by risk.